Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
187 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
AbbVie Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'AbbVie Inc. - Product Pipeline Review - 2014', provides an overview of the AbbVie Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of AbbVie Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of AbbVie Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of AbbVie Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the AbbVie Inc.'s pipeline products Reasons to buy - Evaluate AbbVie Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of AbbVie Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the AbbVie Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of AbbVie Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of AbbVie Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of AbbVie Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 AbbVie Inc. Snapshot 6 AbbVie Inc. Overview 6 Key Information 6 Key Facts 6 AbbVie Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 AbbVie Inc. - Pipeline Review 13 Pipeline Products by Stage of Development 13 Pipeline Products - Monotherapy 14 Pipeline Products - Combination Treatment Modalities 15 Pipeline Products - Partnered Products 16 Pipeline Products - Out-Licensed Products 19 AbbVie Inc. - Pipeline Products Glance 21 AbbVie Inc. - Late Stage Pipeline Products 21 AbbVie Inc. - Clinical Stage Pipeline Products 25 AbbVie Inc. - Early Stage Pipeline Products 29 AbbVie Inc. - Drug Profiles 32 (carbidopa + levodopa) 32 ABT-450/r + ABT-267 + dasabuvir 34 adalimumab 37 ABT-450 39 ABT-450/r + ABT-267 41 ABT-450/r + ABT-267 + RBV 43 atrasentan hydrochloride 45 daclizumab 46 dasabuvir 49 elagolix sodium 51 elotuzumab 53 fluvoxamine maleate 55 ombitasvir 57 paricalcitol 59 veliparib 60 venetoclax + rituximab 62 ABT-122 64 ABT-126 65 ABT-436 67 ABT-493 68 ABT-493 + ABT-530 69 ABT-494 70 ABT-639 71 ABT-719 72 ABT-806 74 ABT-981 75 linifanib 76 navitoclax 78 venetoclax 80 ABT-414 82 ABBV-399 83 ABT-165 84 ABT-354 85 ABT-510 86 ABT-560 88 ABT-614 89 ABT-700 90 ABT-767 91 Antibody Drug Conjugate for Squamous Cell Tumor 92 ilorasertib 93 venetoclax + obinutuzumab 95 volociximab 96 A-1048400 100 A-1264087 101 A-431404 102 A-582941 103 A-705253 105 A-801195 106 A-836339 107 A-887755 108 A-889425 109 A-918446 110 ABT-487 111 ABT-731 112 ABT-737 113 ABT-898 115 Antibody Drug Conjugates for Cancer 116 SLV-330 117 SOL-1 118 AbbVie Inc. - Pipeline Analysis 119 AbbVie Inc. - Pipeline Products by Target 119 AbbVie Inc. - Pipeline Products by Route of Administration 124 AbbVie Inc. - Pipeline Products by Molecule Type 125 AbbVie Inc. - Pipeline Products by Mechanism of Action 126 AbbVie Inc. - Recent Pipeline Updates 131 AbbVie Inc. - Dormant Projects 160 AbbVie Inc. - Discontinued Pipeline Products 168 Discontinued Pipeline Product Profiles 168 AbbVie Inc. - Company Statement 173 AbbVie Inc. - Locations And Subsidiaries 174 Head Office 174 Other Locations & Subsidiaries 174 Appendix 182 Methodology 182 Coverage 182 Secondary Research 182 Primary Research 182 Expert Panel Validation 182 Contact Us 183 Disclaimer 183
List of Tables AbbVie Inc., Key Information 10 AbbVie Inc., Key Facts 10 AbbVie Inc. - Pipeline by Indication, 2014 12 AbbVie Inc. - Pipeline by Stage of Development, 2014 17 AbbVie Inc. - Monotherapy Products in Pipeline, 2014 18 AbbVie Inc. - Combination Treatment Modalities in Pipeline, 2014 19 AbbVie Inc. - Partnered Products in Pipeline, 2014 20 AbbVie Inc. - Partnered Products/ Combination Treatment Modalities, 2014 21 AbbVie Inc. - Out-Licensed Products in Pipeline, 2014 23 AbbVie Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 24 AbbVie Inc. - Pre-Registration, 2014 25 AbbVie Inc. - Filing rejected/Withdrawn, 2014 26 AbbVie Inc. - Phase III, 2014 27 AbbVie Inc. - Phase II, 2014 29 AbbVie Inc. - Phase I, 2014 31 AbbVie Inc. - Preclinical, 2014 33 AbbVie Inc. - Discovery, 2014 35 AbbVie Inc. - Pipeline by Target, 2014 124 AbbVie Inc. - Pipeline by Route of Administration, 2014 128 AbbVie Inc. - Pipeline by Molecule Type, 2014 129 AbbVie Inc. - Pipeline Products by Mechanism of Action, 2014 130 AbbVie Inc. - Recent Pipeline Updates, 2014 135 AbbVie Inc. - Dormant Developmental Projects,2014 164 AbbVie Inc. - Discontinued Pipeline Products, 2014 172 AbbVie Inc., Other Locations 178 AbbVie Inc., Subsidiaries 179
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.